Topic:

R&D

Latest Headlines

Latest Headlines

AMRI buys into proteomics to expand its discovery services

Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.

PPD looks to tamp down pesky placebos with new trial tech

Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.

Edico sells its first Dragen bioinformatics processor

Prenatal testing business Sequenom is the first company to buy the technology, which has applications in any setting in which genetic data needs mapping, sorting and deduplicating.

Report: Google's Calico going on hiring spree after AbbVie tie-up

Calico, Google's semi-secretive biotech venture, stepped into the spotlight with a high-dollar collaboration this week, and now the California startup is mounting a big recruitment effort, according to a report.

WHO calls on drug industry, governments to get Ebola therapies to patients

In a desperate attempt to control the ongoing Ebola outbreak in West Africa, the World Health Organization is appealing to drug companies and international regulatory bodies to work together to get experimental therapies and vaccines out of the lab and into the clinic as soon as possible.

Merck KGaA dives into allergy R&D with platform pact

Facing dwindling sales and a thin late-stage pipeline, Merck KGaA is looking to accelerate its efforts in allergy drug development, signing a deal with an Austrian biotech with hopes of quickly seeding new programs in the field.

Fractyl raises $40M for diabetes treatment via endoscopic surgery

Endoscopic surgery isn't usually associated with diabetes, but Fractyl Laboratories yesterday announced encouraging clinical trial results for its endoscopic procedure to treat Type 2 diabetes and revealed a $40 million Series C financing round led by investment firm Mithril Capital Management.

OncoMed gets back on track as FDA clears another clinical hold

OncoMed is moving on from tandem setbacks in its cancer pipeline now that the FDA has removed its final clinical hold on one of the biotech's oncology candidates, clearing it to resume enrollment in a Phase I study.

Edison's orphan drug misses the mark in Phase II

Edison Pharmaceuticals' in-development rare disease treatment missed its primary endpoint in a mid-stage trial, denting the company's plans for an expansive take on CNS R&D.

Researchers develop self-powered pacemaker system based on automatic wristwatch

As cardiac devicemakers search for innovative ways to streamline products for patients, Swiss researchers have developed a self-powered pacemaker modeled after an automatic wristwatch that could provide an alternative to traditional pacing systems.